Ang, Yvonne L. E.
Ho, Gwo Fuang
Soo, Ross A.
Sundar, Raghav
Tan, Sing Huang
Yong, Wei Peng
Ow, Samuel G. W.
Lim, Joline S. J.
Chong, Wan Qin
Soe, Phyu Pyar
Tai, Bee Choo
Wang, Lingzhi
Goh, Boon Cher
Lee, Soo-Chin http://orcid.org/0000-0001-5341-7369
Funding for this research was provided by:
National Medical Research Council (NMRC/CG/012/2013, NMRC/CG/M005/2017_NCIS, NMRC/CSA-SI/0004/2015)
Article History
Received: 29 July 2020
Accepted: 4 November 2020
First Online: 17 November 2020
Ethics approval and consent to participate
: The study was approved by the institutional review board at each participating centre (Domain Specific Research Board approved on 23rd April 2013 for the Singapore site [Reference number 2013/00170] and Medical Ethics Committee University Malaya Medical Centre on 19th June 2013 for the Malaysia site [Protocol number BR01/08/13]) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.Written informed consent was obtained from all individual participants included in the study.
: Not applicable.
: RAS: Honoraria: Astra Zeneca, BMS, Boehringer Ingelheim, Eli-Lilly, Merck, Novartis, Pfizer, Roche and Taiho; Research grant: Astra-Zeneca.RS: Advisory board: BMS, Merck, Eisai, Bayer, Taiho; honoraria for talks: MSD, Eli Lilly, BMS, Roche, Taiho; Travel funding: Roche, Astra Zeneca, Taiho, Eisai; Research funding: Paxman Coolers, MSD.These are outside the submitted work.SGWO: Honoraria: Pfizer, Astra Zeneca, Novartis, Eli Lily.BCT: Honoraria for workshops: Boehringer Ingelheim; Royalty: Wiley-Blackwell.SCL: Advisory board: Roche, MSD, Astra Zeneca, Pfizer, Novartis, Eli Lilly, ACT Genomics, Eisai; honoraria for talks: Astra Zeneca, Pfizer, Novartis, ACT Genomics, Eisai; Research Funding: Taiho, Eisai, Pfizer, ACT Genomics, ASLAN Pharmaceuticals Ltd.; Travel funding for conferences: Amgen, Pfizer.The other authors declare that they have no competing interests.